J Gastroenterol Hepatol. 2005;20(1):11-25. Parenteral PPI preparations have been available in European and Asian countries for many years. Recently, parenteral pantoprazole has been approved for ...

An Illi­nois ju­ry ruled in fa­vor of Boehringer In­gel­heim in Zan­tac lit­i­ga­tion brought by two prostate can­cer pa­tients, the com­pa­ny con­firmed.

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

An Illinois state jury has today ruled in favor of Boehringer Ingelheim, rejecting claims from two men who alleged that their prostate cancer diagnoses were caused by long-term use of the company’s ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.